Computational modeling and preclinical evaluation support targeting somatic instability for Huntington's disease treatment.

AAV-DB-3.miMSH3 reduces MSH3 mRNA by 48–94% in medium spiny neurons of nonhuman primates, and modeling predicts 50–120% slowing of Huntington’s disease progression.

• Why it matters: Somatic instability of the expanded CAG repeat is implicated as a pathogenic driver in Huntington’s disease, and MSH3 is a therapeutic target linked to disease onset and progression.
• What they did: The study combined an HD patient–informed computational model with preclinical testing of an artificial miRNA against MSH3 delivered by AAV-DB-3 to MSNs, measuring MSH3 mRNA reduction and somatic instability.
• The result: In HdhQ111 mice, AAV-DB-3.miMSH3 reduced somatic instability by up to 46%, and together with the model supports translational potential as a disease-modifying therapy.